Literature DB >> 11841901

Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia.

Campbell Aitken1, Cheryl Delalande, Kay Stanton.   

Abstract

AIMS: To measure exposure to the hepatitis C and B viruses and HIV among Victorian steroid injectors and evaluate associations between exposure and risk behaviour, and report other characteristics of the study group.
DESIGN: Seroprevalence study using a convenience sample.
SETTING: Victoria, Australia. PARTICIPANTS: Current injectors of illicit anabolic steroids. MEASUREMENTS: Prevalences of exposure to HIV and the hepatitis B and C viruses; associations of characteristics and behaviours with exposure; descriptive statistics for the sample.
FINDINGS: Six of 63 blood samples (9.5%) contained hepatitis C virus antibodies; 12.0% tested positive for hepatitis B core antibody; none contained anti-HIV. Hepatitis C virus exposure was associated with heroin injection, imprisonment, sharing needles to inject other drugs, number of tattoos, and hepatitis B virus exposure. No significant differences existed in the steroid-related risk behaviour of exposed and non-exposed individuals. Hepatitis B virus exposure was associated only with hepatitis C virus exposure, past imprisonment and age of first injection.
CONCLUSIONS: Exposure to the hepatitis B and C viruses was detected; hepatitis C virus exposure was at much lower prevalence than normally found among other drug injectors. Factors other than steroid injecting were associated with exposure. Nonetheless, the hepatitis C-exposed reported many steroid-related and other risk behaviours which could spread the virus. Steroid injectors should not be neglected in blood-borne virus prevention efforts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841901     DOI: 10.1016/s0376-8716(01)00174-0

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

Review 1.  Performance-enhancing drugs.

Authors:  Christopher Dandoy; Rani S Gereige
Journal:  Pediatr Rev       Date:  2012-06

Review 2.  Globalisation of anti-doping: the reverse side of the medal.

Authors:  Bengt Kayser; Aaron C T Smith
Journal:  BMJ       Date:  2008-07-04

Review 3.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 4.  Anabolic steroid abuse and dependence.

Authors:  Kirk J Brower
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

Review 5.  Anabolic steroids: dependence and complications of chronic use.

Authors:  Gianluca Quaglio; Anna Fornasiero; Paolo Mezzelani; Stefano Moreschini; Fabio Lugoboni; Alessandro Lechi
Journal:  Intern Emerg Med       Date:  2009-05-26       Impact factor: 3.397

Review 6.  Effects of anabolic-androgens on brain reward function.

Authors:  Emanuela Mhillaj; Maria G Morgese; Paolo Tucci; Maria Bove; Stefania Schiavone; Luigia Trabace
Journal:  Front Neurosci       Date:  2015-08-26       Impact factor: 4.677

7.  Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study.

Authors:  Andreas Kimergård; Jim McVeigh
Journal:  Harm Reduct J       Date:  2014-07-02

8.  Sociodemographic and Health Profile of Heterosexual Men Living With HIV in Ontario, Canada.

Authors:  Kristen M Wheeler; Tony Antoniou; Sandra Gardner; Lucia Light; Ramandip Grewal; Jason Globerman; Winston Husbands; Ann N Burchell
Journal:  Am J Mens Health       Date:  2017-03-01

9.  Current anti-doping policy: a critical appraisal.

Authors:  Bengt Kayser; Alexandre Mauron; Andy Miah
Journal:  BMC Med Ethics       Date:  2007-03-29       Impact factor: 2.652

10.  Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study.

Authors:  Vivian D Hope; Jim McVeigh; Andrea Marongiu; Michael Evans-Brown; Josie Smith; Andreas Kimergård; Sara Croxford; Caryl M Beynon; John V Parry; Mark A Bellis; Fortune Ncube
Journal:  BMJ Open       Date:  2013-09-12       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.